Literature DB >> 19817929

Vanoxerine, a new drug for terminating atrial fibrillation and flutter.

Naomichi Matsumoto1, Celeen M Khrestian, Kyungmoo Ryu, Antonio E Lacerda, Arthur M Brown, Albert L Waldo.   

Abstract

BACKGROUND: Vanoxerine produces potent block of cardiac hERG, sodium, and L-type calcium channels. Block is strongly frequency dependent, is unassociated with transmural dispersion of repolarization, and occurs at concentrations safe in humans. Therefore, we proposed that vanoxerine might be antiarrhythmic. In these studies, we tested the hypothesis that vanoxerine would terminate induced atrial fibrillation (AF) and atrial flutter (AFL) in dogs with sterile pericarditis (SP). METHODS AND
RESULTS: In 9 SP dogs, 11 episodes each of sustained (>10 minutes) AF and AFL were induced. Electrophysiological studies were performed before and after infusion of vanoxerine, which effectively terminated AF and AFL in 19 of 22 episodes. Simultaneous multisite mapping during 3 AF and 3 AFL episodes demonstrated that termination of each arrhythmia occurred with termination of the driver (a reentrant circuit) following an increase in tachycardia CL. Except for conduction in an area of slow conduction in the driver's reentrant circuit, vanoxerine did not significantly affect intraatrial or atrioventricular conduction time, QRS duration, or QT/QTc intervals. Ventricular refractoriness prolonged minimally during ventricular pacing at 400 and 333 ms (176 +/- 16 ms to 182 +/- 16 ms; 173 +/- 11 ms to 178 +/- 18 ms, respectively). Vanoxerine minimally increased (mean 0.7 mA) atrial stimulus threshold for capture.
CONCLUSIONS: Vanoxerine effectively terminated induced, sustained AF and AFL in the canine SP model, and produced insignificant or minimal changes in refractoriness, conduction time, or stimulus threshold, consistent with little proarrhythmic risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817929     DOI: 10.1111/j.1540-8167.2009.01622.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

1.  Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.

Authors:  Ivan Cakulev; Antonio E Lacerda; Celeen M Khrestian; Kyungmoo Ryu; Arthur M Brown; Albert L Waldo
Journal:  J Cardiovasc Electrophysiol       Date:  2011-05-26

Review 2.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

3.  Vanoxerine: cellular mechanism of a new antiarrhythmic.

Authors:  Antonio E Lacerda; Yuri A Kuryshev; Gan-Xin Yan; Albert L Waldo; Arthur M Brown
Journal:  J Cardiovasc Electrophysiol       Date:  2009-10-08

4.  Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.

Authors:  Ying Zhu; Kun-Bin Ke; Zhong-Kun Xia; Hong-Jian Li; Rong Su; Chao Dong; Feng-Mei Zhou; Lin Wang; Rong Chen; Shi-Guo Wu; Hui Zhao; Peng Gu; Kwong-Sak Leung; Man-Hon Wong; Gang Lu; Jian-Ying Zhang; Bing-Hua Jiang; Jian-Ge Qiu; Xi-Nan Shi; Marie Chia-Mi Lin
Journal:  Mol Med       Date:  2021-02-12       Impact factor: 6.354

Review 5.  Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.

Authors:  Dobromir Dobrev; Stanley Nattel; Jordi Heijman; Roddy Hiram; Na Li
Journal:  Nat Rev Cardiol       Date:  2022-09-15       Impact factor: 49.421

6.  Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.

Authors:  Carlos A Obejero-Paz; Andrew Bruening-Wright; James Kramer; Peter Hawryluk; Milos Tatalovic; Howard C Dittrich; Arthur M Brown
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

7.  Systematic review of pre-clinical therapies for post-operative atrial fibrillation.

Authors:  Chanhee Seo; Connor Michie; Benjamin Hibbert; Darryl R Davis
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.